AgingResearch.NewsJoin free

Tacrolimus or Q134R

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Institute on Aging and 1 more
  • Animals1

Outcomes

2

Cognitive decline

downin dogs1

1 study

  1. Tacrolimus or Q134R protects against cognitive decline in dogs.

    “there was improvement in spatial learning, as well as maintenance of memory, attention, and working memory relative to placebo dogs.”

    AnimalsMaintenance of memory, attention, and working memory relative to placebo dogsthree yearsn = 37

    Calcineurin/NFAT inhibitors maintain cognition in a preclinical prevention study in an aging canine model of Alzheimer disease

    Neurobiology of aging10 Nov 2024

Spatial learning

upin dogs1

1 study

  1. Tacrolimus or Q134R improves spatial learning in dogs.

    “there was improvement in spatial learning, as well as maintenance of memory, attention, and working memory relative to placebo dogs.”

    AnimalsBeagles receiving tacrolimus or Q134R compared with placebo dogsthree yearsn = 37

    Calcineurin/NFAT inhibitors maintain cognition in a preclinical prevention study in an aging canine model of Alzheimer disease

    Neurobiology of aging10 Nov 2024

Latest

Related